Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression.

Area of Science:

• Microbiome research
• Neuropsychiatry
• Genomics

Background:

• Neuropsychiatric disorders (NPDs), including anxiety disorder (ANXD) and major depressive disorder (MDD), are complex conditions with poorly understood etiologies.
• The gut microbiota's role in brain function and mental health is an emerging area of research, often referred to as the gut-brain axis.

Approach:

• The study analyzed 666 fecal samples from the Tulsa-1000 and NeuroMAP CoBRE cohorts using 16S rRNA gene amplicon and shallow shotgun sequencing.
• Medication use, specifically antidepressants and anxiolytics (ATC classification), was assessed for its impact on gut microbial composition.
• Machine learning models, including Random Forest classifiers, were employed to predict NPD diagnoses and medication status from microbial profiles.

Key Points:

• Antidepressant use demonstrated a significant effect on gut microbiota beta diversity, with a larger effect size than NPD diagnosis.
• Specific microbial taxa were identified and associated with ANXD and MDD, suggesting potential targets for non-pharmacological interventions.
• Microbial profiles showed promise in predicting NPD diagnoses and medication usage, indicating potential as diagnostic biomarkers.

Conclusions:

• Gut microbiota composition is significantly influenced by antidepressant medication, impacting the understanding of NPD pathophysiology.
• The identified microbial associations with ANXD and MDD open avenues for novel therapeutic strategies.
• Gut microbiota analysis presents a promising, non-invasive approach for diagnosing NPD and monitoring treatment response.